Overview
Autoimmune pancreatitis type 2 (AIP type 2), also known as idiopathic duct-centric pancreatitis (IDCP) or granulocytic epithelial lesion (GEL)-positive pancreatitis, is a rare inflammatory disorder of the pancreas. Unlike autoimmune pancreatitis type 1, which is part of the systemic IgG4-related disease spectrum, AIP type 2 is a pancreas-specific condition characterized by neutrophilic infiltration of the pancreatic duct epithelium (granulocytic epithelial lesions) without elevated serum IgG4 levels. It primarily affects the exocrine pancreas, leading to pancreatic enlargement, ductal narrowing, and impaired pancreatic function. Patients typically present with obstructive jaundice, abdominal pain, and acute pancreatitis. AIP type 2 tends to affect younger individuals compared to type 1, often presenting in the fourth to fifth decade of life, and affects males and females equally. A notable clinical association exists with inflammatory bowel disease (IBD), particularly ulcerative colitis, which is found in a significant proportion of patients. Unlike type 1, AIP type 2 does not typically involve other organs and serum autoantibody markers are generally absent, making diagnosis more challenging and often requiring histological confirmation through biopsy or surgical resection specimens. Treatment for AIP type 2 centers on corticosteroid therapy, which is highly effective in inducing remission. Most patients respond well to an initial course of oral corticosteroids such as prednisone, with gradual tapering over several weeks. A key advantage of AIP type 2 over type 1 is its significantly lower relapse rate; recurrence after successful steroid treatment is uncommon. In cases where the disease mimics pancreatic cancer on imaging, accurate diagnosis is critical to avoid unnecessary surgical resection. Long-term prognosis is generally favorable with appropriate treatment, though monitoring for associated inflammatory bowel disease is recommended.
Also known as:
Multifactorial
Caused by a mix of several genes and environmental factors
Adult
Begins in adulthood (age 18 or older)
Treatments
No FDA-approved treatments are currently listed for Autoimmune pancreatitis type 2.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Autoimmune pancreatitis type 2 at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Autoimmune pancreatitis type 2.
Community
No community posts yet. Be the first to share your experience with Autoimmune pancreatitis type 2.
Start the conversation →Latest news about Autoimmune pancreatitis type 2
No recent news articles for Autoimmune pancreatitis type 2.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Autoimmune pancreatitis type 2
What is Autoimmune pancreatitis type 2?
Autoimmune pancreatitis type 2 (AIP type 2), also known as idiopathic duct-centric pancreatitis (IDCP) or granulocytic epithelial lesion (GEL)-positive pancreatitis, is a rare inflammatory disorder of the pancreas. Unlike autoimmune pancreatitis type 1, which is part of the systemic IgG4-related disease spectrum, AIP type 2 is a pancreas-specific condition characterized by neutrophilic infiltration of the pancreatic duct epithelium (granulocytic epithelial lesions) without elevated serum IgG4 levels. It primarily affects the exocrine pancreas, leading to pancreatic enlargement, ductal narrowin
How is Autoimmune pancreatitis type 2 inherited?
Autoimmune pancreatitis type 2 follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Autoimmune pancreatitis type 2 typically begin?
Typical onset of Autoimmune pancreatitis type 2 is adult. Age of onset can vary across affected individuals.
Which specialists treat Autoimmune pancreatitis type 2?
1 specialists and care centers treating Autoimmune pancreatitis type 2 are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.